1 not yet recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow pLGG With BRAF Alteration: new trials by email Literature Review of pLGG With BRAF Alteration trials Research Report on pLGG With BRAF Alteration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration Luvometinib, Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide - Low-grade Glioma, Pediatric Low-grade Gliomas | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-06-30 | 2025-06-04 |
Carboplatin (1) · Temozolomide (1) · Vindesine (1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)
China (1)